Windlas Biotech has informed the stock exchanges of an upcoming Board of Directors meeting scheduled for Thursday, May 21, 2026. The notice has been issued pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to consider and approve key financial and corporate matters. The following items are on the agenda for the meeting:

Trading Window Closure

In accordance with the company's code of conduct to regulate, monitor, and report trading by Designated Persons under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window of the company has been closed since April 1, 2026. The Trading Window will reopen after the expiry of 48 hours from the date of declaration of the financial results.

The notice was issued on May 15, 2026, and signed by Ananta Narayan Panda, Company Secretary & Compliance Officer of Windlas Biotech.

Windlas Biotech Limited announced a change in its board of directors on May 5, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors, through a resolution dated May 5, 2026, approved the appointment of a new Independent Woman Director and acknowledged the cessation of an existing Independent Director upon completion of his term. The intimation was filed with both BSE Limited and the National Stock Exchange of India Limited by Company Secretary and Compliance Officer Ananta Narayan Panda.

Board-Level Changes at a Glance

The two key changes to the board composition are summarised below:

Appointment of Dr. Tarashree Singhal

Dr. Tarashree Singhal has been appointed as an Additional Director and Independent Woman Director of Windlas Biotech with effect from May 5, 2026, based on the recommendation of the Nomination and Remuneration Committee. The appointment is for a period of five consecutive years and remains subject to the approval of shareholders. Dr. Tarashree Singhal holds an MBBS Degree from Mysore University and a PG Diploma in Ultrasonography from Annamalai University, and brings over 26 years of experience as a medical practitioner. She has been confirmed as not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Her relationship with other directors has been disclosed as independent.

Cessation of Mr. Srinivasan Venkataraman

Mr. Srinivasan Venkataraman (DIN: 01132306) has completed his five-year term as an Independent Director of the company. He ceases to be a director with effect from the close of business hours on May 5, 2026, with the effective date of cessation being May 6, 2026. Consequent to his cessation as a director, Mr. Venkataraman also ceases to be a member and chairman of the committees on which he served.

Regulatory Compliance

The disclosures pertaining to this change in directorate have been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular Ref: HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The detailed profile of Dr. Tarashree Singhal was submitted as Annexure I along with the regulatory filing.